Genomic Approach

Genetic testing vs. Genomic testing

Genetic tests typically screen for inherited risk factors or spontaneously arising mutations. They can help identify the risk of getting cancer or how a tumor will respond to certain therapies.1

Genomic tests examine gene expression levels within a sample of tumor tissue. They provide information about the tumor’s biology and aggressiveness.1

Clinical features alone may not show the whole picture

Although biopsies provide important information, they sample very small areas of the prostate and may incorrectly represent true prostate pathology.2 The Oncotype DX GPS assay is designed to provide detailed information to more confidently assess risk and guide treatment decisions for your clinically low- and intermediate-risk prostate cancer patients.

 

Prostate cancer case study with the Oncotype DX® GPS™ test

See how the Oncotype DX Genomic Prostate Score test revealed aggressive tumor biology for a patient who initially seemed like a strong candidate for active surveillance.

 

Rigorous development and clinical validation

The Oncotype DX Genomic Prostate Score was developed in collaboration with the Cleveland Clinic and UCSF to specifically address the many challenges inherent to prostate cancer risk assessment.3-4 It was then clinically validated in two large, contemporary studies as a strong, independent predictor of adverse pathology at radical prostatectomy.3,5


The genes in the Oncotype DX GPS assay were chosen for their:

  • Correlation with tumor aggressiveness regardless of multifocality or heterogeneity
  • Performance in biopsy samples with small tumor volume

Funnel Visual

Multiple biologic pathways were more predictive than any single pathway alone3

ANDROGEN SIGNALING CELLULAR ORGANIZATION STROMAL RESPONSE CELLULAR PROLIFERATION REFERENCE
AZGP1
FAM13C
KLK2
SRD5A2
FLNC
GSN
GSTM2
TPM2
BGN
COL1A1
SFRP4
TPX2 ARF1
ATP5E
CLTC
GPS1
PGK1


REFERENCES

  1. National Human Genome Research Institute. 2018.
  2. Gearman et al. J Urol. 2017.
  3. Klein et al. Eur Urol. 2014.
  4. Knezevic et al. BMC Genomics. 2013.
  5. Cullen et al. Eur Urol. 2015.
National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. NCCN does not endorse any product or therapy.

Making cancer care smarter.™
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.